当前位置: X-MOL 学术BMC Fam. Pract. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
QUality improvement in primary care to prevent hospitalisations and improve Effectiveness and efficiency of care for people Living with coronary heart disease (QUEL): protocol for a 24-month cluster randomised controlled trial in primary care.
BMC Family Practice ( IF 2.9 ) Pub Date : 2020-02-14 , DOI: 10.1186/s12875-020-01105-0
Julie Redfern 1, 2, 3 , Nashid Hafiz 1 , Karice Hyun 1 , Andrew Knight 4, 5 , Charlotte Hespe 6 , Clara K Chow 1, 2 , Tom Briffa 7 , Robyn Gallagher 8 , Christopher Reid 9 , David L Hare 10 , Nicholas Zwar 11 , Mark Woodward 5, 12 , Stephen Jan 3 , Emily R Atkins 3 , Tracey-Lea Laba 13 , Elizabeth Halcomb 14 , Laurent Billot 3 , Tracey Johnson 15 , Timothy Usherwood 3, 16
Affiliation  

BACKGROUND Cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, is the leading cause of death and disability globally. A large proportion of mortality occurs in people with prior CHD and effective and scalable strategies are needed to prevent associated deaths and hospitalisations. The aim of this study is to determine if a practice-level collaborative quality improvement program, focused on patients with CHD, reduces the rate of unplanned CVD hospitalisations and major adverse cardiovascular events, and increases the proportion of patients achieving risk factor targets at 24 months. METHODS Cluster randomised controlled trial (cRCT) to evaluate the effectiveness of a primary care quality improvement program in 50 primary care practices (n~ 10,000 patients) with 24-month follow-up. Eligible practices will be randomised (1:1) to participate in either the intervention (collaborative quality improvement program) or control (standard care) regimens. Outcomes will be assessed based on randomised allocation, according to intention-to-treat. The primary outcome is the proportion of patients with unplanned CVD hospitalisations at 2 years. Secondary outcomes are proportion of patients with major adverse cardiovascular events, proportion of patients who received prescriptions for guideline-recommended medicines, proportion of patients achieving national risk factor targets and proportion with a chronic disease management plan or review. Differences in the proportion of patients who are hospitalised (as well as binary secondary outcomes) will be analysed using log-binomial regression or robust Poisson regression, if necessary. DISCUSSION Despite extensive research with surrogate outcomes, to the authors' knowledge, this is the first randomised controlled trial to evaluate the effectiveness of a data-driven collaborative quality improvement intervention on hospitalisations, CVD events and cardiovascular risk amongst patients with CHD in the primary care setting. The use of data linkage for collection of outcomes will enable evaluation of this potentially efficient strategy for improving management of risk and outcomes for people with heart disease. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR) number ACTRN12619001790134 (dated 20th December 2019).

中文翻译:

改善初级保健的质量,以防止住院和提高对冠心病患者(QUEL)的护理的有效性和效率:一项针对初级保健的24个月群集随机对照试验的方案。

背景技术心血管疾病(CVD),包括冠心病(CHD)和中风,是全球死亡和残疾的主要原因。患有冠心病的人中有很大一部分死亡,因此需要有效且可扩展的策略来预防相关的死亡和住院。这项研究的目的是确定针对冠心病患者的实践水平的协作质量改善计划是否降低计划外的CVD住院率和重大心血管不良事件的发生率,并增加在24个月内达到危险因素目标的患者比例。方法采用整群随机对照试验(cRCT)评估50例初级保健实践(n〜10,000例患者)中初级保健质量改善计划的有效性,并进行24个月的随访。符合条件的做法将被随机分配(1:1),以参与干预(协作质量改进计划)或对照(标准护理)方案。结果将根据意向性治疗基于随机分配进行评估。主要结局是2年内计划外CVD住院的患者比例。次要结局是具有重大心血管不良事件的患者比例,接受指南推荐药物处方的患者比例,达到国家危险因素目标的患者比例以及具有慢性病管理计划或审查的比例。必要时,将使用对数二项回归或稳健的Poisson回归分析住院患者比例的差异(以及二元次要结局)。讨论尽管作者进行了广泛的研究并获得了替代结果,但这还是第一项随机对照试验,旨在评估以数据为基础的协作质量改善干预措施在初级保健中冠心病患者中住院,CVD事件和心血管风险的有效性。设置。使用数据链接收集结果将有助于评估这种潜在有效的策略,以改善心脏病患者的风险和结果管理。试验注册澳大利亚新西兰临床试验注册(ANZCTR)编号ACTRN12619001790134(日期为2019年12月20日)。这是第一项随机对照试验,旨在评估在初级保健机构中以数据为依据的协作质量改善干预措施对冠心病患者的住院,CVD事件和心血管风险的有效性。使用数据链接收集结果将有助于评估这种潜在有效的策略,以改善心脏病患者的风险和结果管理。试验注册澳大利亚新西兰临床试验注册(ANZCTR)编号ACTRN12619001790134(日期为2019年12月20日)。这是第一项随机对照试验,旨在评估在初级保健机构中以数据为依据的协作质量改善干预措施对冠心病患者的住院,CVD事件和心血管风险的有效性。使用数据链接收集结果将有助于评估这种潜在有效的策略,以改善心脏病患者的风险和结果管理。试验注册澳大利亚新西兰临床试验注册(ANZCTR)编号ACTRN12619001790134(日期为2019年12月20日)。使用数据链接收集结果将有助于评估这种潜在有效的策略,以改善心脏病患者的风险和结果管理。试验注册澳大利亚新西兰临床试验注册(ANZCTR)编号ACTRN12619001790134(日期为2019年12月20日)。使用数据链接收集结果将有助于评估这种潜在有效的策略,以改善心脏病患者的风险和结果管理。试验注册澳大利亚新西兰临床试验注册(ANZCTR)编号ACTRN12619001790134(日期为2019年12月20日)。
更新日期:2020-04-22
down
wechat
bug